EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene‐negative

The use of immune checkpoint inhibitors targeting PD‐1 and PD‐L1 in advanced non‐small cell lung cancer (NSCLC) has been one of the most significant improvements in recent years. However the resistance mechanisms of immune checkpoint inhibitors require further investigation. Herein we attempted to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Chen, Zeng, Fanxu, Zhang, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501009/
https://www.ncbi.nlm.nih.gov/pubmed/30810279
http://dx.doi.org/10.1111/1759-7714.13023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501009/
https://www.ncbi.nlm.nih.gov/pubmed/30810279
http://dx.doi.org/10.1111/1759-7714.13023

Ejemplares similares